Influence of antiretroviral therapy on liver disease

Current Opinion in HIV and AIDS

Volumn 6, Issue 4, 2011, Pages 272-277

  Kovari, Helen ^a   Weber, Rainer ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

antiretroviral therapy; hepatitis virus coinfections; HIV; liver

Indexed keywords

ALANINE AMINOTRANSFERASE; BMI1 PROTEIN; DIDANOSINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE;

ALCOHOL CONSUMPTION; DISEASE ASSOCIATION; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HYPERTENSION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; VIRUS HEPATITIS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS;

EID: 79959360426     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283473405     Document Type: Review

References (61)

1. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641. (Pubitemid 44232373)
2. Crum-Cianflone N, Collins G, Medina S, et al. Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons. Clin Gastroenterol Hepatol 2010; 8:183-191. In this cross-sectional study, the prevalence and causes of liver test abnormalities among HIV-infected patients of a US military cohort were studied.
3. Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011; 18:11-16. In this large cross-sectional study, 681 HIV-infected patients underwent examination by transient elastometry. The prevalence and risk factors associated with advanced liver fibrosis in HIV/HCV-coinfected and HIV-monoinfected patients are described.
4. Kovari H, Ledergerber B, Battegay M, et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. Clin Infect Dis 2010; 50:502-511. In this analysis of the Swiss HIV Cohort Study, the incidence and associated risk factors for chronic elevated ALT values in HIV-monoinfected patients were evaluated. The strengths of this study are the large number of patient-years with prospectively collected anthropometric, laboratory, and clinical data including assessment of alcohol use.
5. Merchante N, Perez-Camacho I, Mira JA, et al. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. Antivir Ther 2010; 15:753-763. In this cross-sectional prospective study including 258 HIV-monoinfected patients without known liver disease, the prevalence of and associated factors for abnormal liver stiffness measured by transient elastography were evaluated.
6. DallaPiazza M, Amorosa VK, Localio R, et al. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 2010; 10:116. This cross-sectional study among HIV-monoinfected patients analyzed the prevalence of and associated factors for significant liver fibrosis measured by the APRI score.
7. Sterling RK, Chiu S, Snider K, et al. The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. Dig Dis Sci 2008; 53:1375-1382. (Pubitemid 351514650)
8. Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50:464-473.
9. Ryan P, Blanco F, Garcia-Gasco P, et al. Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. HIV Med 2009; 10:53-59.
10. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55. (Pubitemid 41772515)
11. Blackard JT, Sherman KE. HCV/HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008; 15:323-330.
12. Tuyama AC, Hong F, Saiman Y, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010; 52:612-622. This is an in-vitro study demonstrating the possibility that HIV enters hepatic stellate cells that induce collagen production and secretion of the pro-inflammatory cytokine chemoattractant protein-1.
13. Claudio GA, Martin AF, de Dios Perrino S, et al. DRESS syndrome associated with nevirapine therapy. Arch Intern Med 2001; 161:2501-2502. (Pubitemid 33043125)
14. Moyle GJ, Datta D, Mandalia S, et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16:1341-1349. (Pubitemid 34722065)
15. Mocroft A, Soriano V, Rockstroh J, et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005; 19:2117-2125.
16. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19:585-592. (Pubitemid 40543981)
17. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43:365-372. (Pubitemid 44078910)
18. Nunez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010; 52:1143-1155. This is a comprehensive review on the pathomechanisms in ART-related liver injury, description of clinical syndromes due to ART-associated hepatotoxicity and on its management.
19. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gammaglutamyltransferase and mortality in the United States population. Gastroenterology 2009; 136:477-485; e411.
20. Mohammed SS, Aghdassi E, Salit IE, et al. HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients. J Acquir Immune Defic Syndr 2007; 45:432-438. (Pubitemid 47057670)
21. Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47:250-257. (Pubitemid 351920629)
22. Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007; 25:883-889.
23. Ingiliz P, Valantin MA, Duvivier C, et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49:436-442.
24. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
25. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21:187-192. (Pubitemid 46036926)
26. Schiano TD, Kotler DP, Ferran E, et al. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102:2536-2540. (Pubitemid 47631766)
27. Maida I, Garcia-Gasco P, Sotgiu G, et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13:103-107. (Pubitemid 351541679)
28. Saifee S, Joelson D, Braude J, et al. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol 2008; 6:1167-1169.
29. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case - control study. Clin Infect Dis 2009; 49:626-635.
30. Vispo E, Moreno A, Maida I, et al. Noncirrhotic portal hypertension in HIVinfected patients: unique clinical and pathological findings. AIDS 2010; 24:1171-1176. In this case series, 12 HIV-positive individuals with noncirrhotic portal hypertension are described with respect to epidemiological, clinical, and histological features.
31. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-1058. (Pubitemid 29458296)
32. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926. (Pubitemid 35472132)
33. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569. (Pubitemid 32709592)
34. Deng LP, Gui XE, Zhang YX, et al. Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. World J Gastroenterol 2009; 15:996-1003.
35. Matthews GV, Cooper DA, Dore GJ. Improvements in parameters of endstage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir. Antivir Ther 2007; 12:119-122. (Pubitemid 46340434)
36. Tuma P, Medrano J, Resino S, et al. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. Antivir Ther 2010; 15:881-886. In this longitudinal cohort study, 508 HIV-infected patients with chronic hepatitis B or C coinfection were periodically assessed by transient elastography during a mean follow-up of 2.6 years. It could be shown that the risk of developing cirrhosis was negligible in patients who cleared HCV with therapy or HIV/HBV-coinfected patients on long-term tenofovir-containing ART.
37. de Vries-Sluijs TE, Reijnders JG, Hansen BE, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010; 139:1934-1941. A multicenter cohort study investigating on the long-term efficacy of tenofovir in HIV/HBV-coinfected patients.
38. Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 2008; 48:1062-1069.
39. Piroth L, Pol S, Lacombe K, et al. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. J Hepatol 2010; 53:1006-1012. This retrospective multicenter cohort study comparing the management and efficacy of treatments for chronic hepatitis B in HIV-positive and HIV-negative patients showed that the assessment of chronic HBV and the efficacy of HBV therapy have improved in HIV-positive patients and that HIV infection did not have a negative impact on the likelihood of HBV therapeutic success.
40. Matthews GV, Seaberg E, Dore GJ, et al. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS 2009; 23:1707-1715.
41. Pineda JA, Gonzalez J, Ortega E, et al. Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients. J Viral Hepat 2010; 17:714-719. The prevalence of and factors associated with significant liver fibrosis measured by transient elastography were assessed in HIV/HCV-coinfected patients in a large cross-sectional multicenter study. Older age, daily alcohol intake, the duration of HCV infection, and low CD4 levels were related with fibrosis.
42. Rohrbach J, Robinson N, Harcourt G, et al. Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut 2010; 59:1252-1258. A longitudinal study with long-term follow-up evaluating the impact of HIV and cART on HCV-specific cellular immune responses and HCV RNA levels.
43. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713. (Pubitemid 37468321)
44. Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46:622-630. (Pubitemid 47436106)
45. Sterling RK, Wegelin JA, Smith PG, et al. Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: analysis of paired liver biopsy samples. Clin Gastroenterol Hepatol 2010; 8:1070-1076. In this longitudinal cohort study using paired biopsy, there was no significant difference in liver fibrosis progression between HIV/HCV-coinfected and HCV-monoinfected patients. Most of the coinfected patients were on suppressive ART.
46. Grunhage F,Wasmuth JC, Herkenrath S, et al. Transient elastography discloses identical distribution of liver fibrosis in chronic hepatitis C between HIV-negative and HIV-positive patients on HAART. Eur J Med Res 2010; 15:139-144.
47. Neau D, Winnock M, Castera L, et al. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hepatites virales CO3 Aquitaine Cohort. J Acquir Immune Defic Syndr 2007; 45:168-173. (Pubitemid 46869809)
48. Castera L, Loko MA, Le Bail B, et al. Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype. Aliment Pharmacol Ther 2007; 26:1489-1498. (Pubitemid 350178805)
49. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a metaanalysis of the risk factors. Hepatology 2010; 52:71-78. This meta-analysis investigated into risk factors for hepatic steatosis in HIV/HCV-coinfected patients. Across trials, higher BMI and diabetes mellitus were associated with steatosis. No associations were found between HIV-related factors, including viral load, CD4 cell count, antiretroviral therapy, and class of medication.
50. Woreta TA, Sutcliffe CG, Mehta SH, et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2011; 140:809-817. A prospective longitudinal study using paired liver biopsy data of HIV/HCV-coinfected patients found longer ART exposure and higher CD4 levels to be protective against steatosis.
51. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2011; 1-166. http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed February 2011] These are the current treatment guidelines for the treatment of HIV-positive individuals of the DHHS, USA.
52. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-333. These are the current treatment guidelines for the treatment of HIV-positive individuals of the IAS, USA.
53. European AIDS Clinical Society (EACS) guidelines. Clinical management and treatment of HIV-infected adults in Europe. Version 5. November 2009.
54. Wit FW, Weverling GJ, Weel J, et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31. (Pubitemid 34666910)
55. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-287. (Pubitemid 32702341)
56. Macias J, Mira JA, Lopez-Cortes LF, et al. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther 2006; 11:839-846. (Pubitemid 44736175)
57. Berenguer J, Bellon JM, Miralles P, et al. Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2008; 46:137-143. (Pubitemid 351263575)
58. Vispo E, Mena A, Maida I, et al. Hepatic safety profile of raltegravir in HIVinfected patients with chronic hepatitis C. J Antimicrob Chemother 2010; 65:543-547. This prospective observational study demonstrated a good hepatic safety profile of raltegravir in HIV/HCV-coinfected patients.
59. Velasco M, Moran A, Tellez MJ. Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. N Engl J Med 1999; 340:1765-1766. (Pubitemid 29252611)
60. Perez-Olmeda M, Garcia-Samaniego J, Soriano V. Hepatitis Cviraemia in HIVHCV co-infected patients having immune restoration with highly active antiretroviral therapy. AIDS 2000; 14:212. (Pubitemid 30116453)
61. Bellini C, Keiser O, Chave JP, et al. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Med 2009; 10:12-18.